2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N17771
    (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate 1987871-73-7
    (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate is a selective α-glucosidase inhibitor (IC50=10.53 μg/mL) with anti-hepatic fibrosis and anti-diabetic properties. It also inhibits the growth of mouse hepatic stellate cells (t-HSC/Cl-6) with an IC50 of 109.2 μg/mL. (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate can be isolated from the ester derivatives of Impatiens balsamina L. flowers. (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate can be used in research related to hepatic fibrosis and type 2 diabetes.
    (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate
  • HY-N17773
    Hydrangeic acid 491-79-2
    Hydrangeic acid is an orally effective stilbene-type glycolipid metabolism regulator that lowers blood glucose and lipids. It can be isolated from processed leaves of Hydrangea macrophylla var. thunbergii. Hydrangeic acid is associated with glycolipid metabolism and insulin sensitivity regulation. Hydrangeic acid does not directly activate PPARγ or PPARα, but instead upregulates the mRNA expression of adiponectin, PPARγ2, GLUT4, and fatty acid-binding protein aP2, and downregulates TNF-α mRNA expression, promoting adipogenesis, glucose uptake, and GLUT4 translocation in 3T3-L1 cells. Simultaneously, Hydrangeic acid inhibits inflammatory factor-induced NO production, exerting activity in improving insulin resistance. Hydrangeic acid can be used in research related to type 2 diabetes and does not cause liver weight gain as a side effect.
    Hydrangeic acid
  • HY-N17780
    Picfeoside A 871115-75-2
    Picfeoside A is a phenylethanoid glycoside compound that can be isolated from Picria felterrae Lour. Picfeoside A can be used in research related to diseases such as fever, herpes infections, cancer, and inflammation.
    Picfeoside A
  • HY-N17816
    Tambulin 571-72-2 98%
    Tambulin is an orally active flavonol compound found in Zanthoxylum armatum. Tambulin can inhibit cell proliferation, induce apoptosis and inhibit ROS production. Tambulin upregulates cleaved caspase-3, cleaved caspase-9, and Bax, downregulates Bcl-2 levels. Tambulin can stimulate glucose-dependent insulin secretion and induce endothelium-independent vasorelaxation. Tambulin binds to succinate dehydrogenase (SDH) (Ki = 11.02 μM) and shows significant ferric reducing power. Tambulin can enhances oxidative stress resistance, reduces, lipofuscin deposits, lipid levels, α-synuclein levels, improves locomotary behavior, and dopamine levels in in age-synchronized L1 hermaphrodite Caenorhabditis elegans models of ageing and Parkinson's disease. Tambulin can be used for the researches of Parkinson's disease, lung squamous cell carcinoma, and diabetes.
    Tambulin
  • HY-N17855
    Guavinoside B 372955-18-5
    Guavinoside B is an orally active α-glucosidase inhibitor with an IC50 of 0.21 mM. Guavinoside B upregulates the expressions of Nrf2, GCLC and NQO1 induced by Acetaminophen (HY-66005), downregulates the expression of p-JNK, and reduces intracellular ROS levels. Guavinoside B decreases serum TNF-α levels induced by Acetaminophen, alleviates hepatocellular infiltration and necrosis, and improves liver-related biochemical parameters. Guavinoside B is applicable to the research of diabetes and Acetaminophen-induced liver injury.
    Guavinoside B
  • HY-N17876
    Royleanonic acid 350590-46-4
    Royleanonic acid is an abietan-type diterpene found in the leaves of Salvia officinalis L. Royleanonic acid is a porcine pancreatic lipase inhibitor with an IC50 of 35 μg/mL.
    Royleanonic acid
  • HY-N17914
    Smilaxchinoside A 935530-84-0
    Smilaxchinoside A is an orally active steroidal glycoside found in the roots of S. riparia. Smilaxchinoside A reduces serum uric acid levels and shows potent uricosuric activity. Smilaxchinoside A inhibits XOD activity and downregulates renal mURAT1 expression. Smilaxchinoside A can be used for the research of hyperuricemia.
    Smilaxchinoside A
  • HY-N17925
    Falandioside B 1809429-26-2
    Falandioside B is an α-glucosidase inhibitor with an IC50 of 107.52 μM. Falandioside B scavenges ABTS radical cations. Falandioside B is applicable to research related to postprandial hyperglycemia.
    Falandioside B
  • HY-N17985
    Kalopanaxsaponin H 119742-55-1 98%
    Kalopanaxsaponin H is an hederagenin glycoside (saponin) with no hypoglycemic activity upon intraperitoneal injection. Kalopanaxsaponin H can be metabolized by human intestinal bacteria into Kalopanaxsaponin I, Kalopanaxsaponin A, hederagenin 3-O-α-L-arabinopyranoside and hederagenin, among which Kalopanaxsaponin I and hederagenin are the main metabolites. Kalopanaxsaponin H is isolated from the stem bark of Kalopanax pictus and is used in diabetes-related research.
    Kalopanaxsaponin H
  • HY-N17992
    Gypenoside UL5 1443433-27-9 98%
    Gypenoside UL5 (Compound UL5) is a dammarane-type triterpene saponin found in Gynostemma pentaphyllum. Gypenoside UL5 shows liver injury-inhibiting, anti-inflammatory and antioxidant properties. Gypenoside UL5 can be used for the research of hepatitis, fatty liver, and liver fibrosis.
    Gypenoside UL5
  • HY-N17996
    3'-O-Methy isosaponarin 2803327-85-5 98%
    3'-O-Methylisosaponarin is a spsoscoparin glycoside found in the leaves of C. sativus cultivar Chinese Yellow. 3'-O-Methylisosaponarin shows weak anti-lipase activity. 3'-O-Methylisosaponarin can be used for the research of disturbances of lipid metabolism.
    3'-O-Methy isosaponarin
  • HY-N18018
    Tetrahydroswertianolin 189289-76-7 98%
    Tetrahydroswertianolin (Compound 1) is a tetrahydroxyxanthone glycoside that can be isolated from the whole plant of Swertia japonica Makino. Tetrahydroswertianolin reduces the elevated blood ALT levels in mice with immune-induced liver injury and exhibits protective activity against liver injury. Tetrahydroswertianolin can be used in studies related to anthelmintic, antipyretic and immune-induced liver injury.
    Tetrahydroswertianolin
  • HY-N18019
    Tetrahydro bellidifolin 189289-77-8 98%
    Tetrahydro bellidifolin (Compound 1a) is the aglycone obtained from the hydrolysis of Tetrahydroswertianolin (HY-N18018) by β-glucosidase. Tetrahydro bellidifolin exhibits significant hepatoprotective activity and reduce serum ALT levels. Tetrahydro bellidifolin can be used for the research of liver injury.
    Tetrahydro bellidifolin
  • HY-N18020
    Saurufuran A 425368-86-1 98%
    Saurufuran A is a PPARγ agonist with an EC50 of 16.7 μM. Saurufuran A is applicable to research related to type 2 diabetes, inflammatory diseases and certain cancers.
    Saurufuran A
  • HY-N18033
    Glyceollin III 61080-23-7
    Glyceollin III is a glyceollin found in soybeans. Glyceollin III enhances insulin-stimulated glucose uptake and increases glucagon-like peptide-1 (GLP-1) secretion. Glyceollin III can be used for the research of type 2 diabetes.
    Glyceollin III
  • HY-N18049
    Decussatin 20882-69-3 98%
    Decussatin is an α-Amylases inhibitor isolated from the Tibetan medicinal plant Swertia mussotii. By inhibiting the catalytic activity of α-Amylases, Decussatin reduces the hydrolysis of complex carbohydrates such as starch and the intestinal absorption of glucose, thereby lowering blood glucose levels in the body. Decussatin shows no significant in vitro antibacterial or antifungal activity. Decussatin can be used for the research of type 2 diabetes.
    Decussatin
  • HY-N18066
    Esculeogenin A 854381-37-6 98%
    Esculeogenin A is the sapogenol of tomato saponin Esculeoside A (HY-N18067). Esculeogenin A is an orally active hepatoprotective, hypolipidemic, and antioxidant agent. Esculeogenin A regulates molecular targets like PPARα, SREBP1, Nrf2, NF-κB, ACAT1/ACAT2 to promote hepatic fatty acid oxidation, suppress de novo lipogenesis, enhance antioxidant defense, and inhibit inflammation. Esculeogenin A improves liver function, alleviates hyperlipidemia, and inhibits hepatic steatosis and foam cell formation, preventing nonalcoholic fatty liver disease in high-fat-diet-fed rats and reducing atherosclerotic lesions in apoE-deficient mice. Esculeogenin A can be used for the research of nonalcoholic fatty liver disease, atherosclerosis, and hyperlipidemia.
    Esculeogenin A
  • HY-N18091
    Tovophyllin A 40738-44-1 98%
    Tovophyllin A is an orally active xanthonoid compound. Tovophyllin A exerts neuroprotective effects against Parkinson's disease by activating the Akt/GSK3β signaling pathway. Tovophyllin A protects mouse models of liver injury by activating Nrf2. Tovophyllin A exhibits protective anti-inflammatory activity in mouse models of acute lung injury. Tovophyllin A inhibits the activation of NF-κB and subsequent release of pro-inflammatory cytokines. Tovophyllin A reduces apoptotic cell death (Apoptosis). Tovophyllin A has antiplasmodial activity. Tovophyllin A shows cytotoxic activity against lung epithelial cancer cells and breast cancer cells. Tovophyllin A can be used in research related to Parkinson's disease, liver injury, acute lung injury, lung epithelial cancer, and breast cancer.
    Tovophyllin A
  • HY-N18114
    rel-(E)-6,7-Transdihydroxyligustilide 162426-22-4 98%
    rel-(E)-6,7-Transdihydroxyligustilide is a compound found in the dried tuberous roots of Polygonum multiflorum. rel-(E)-6,7-Transdihydroxyligustilide inhibits Ca2+‑ATPase in calmodulin-deficient human erythrocyte membranes. rel-(E)-6,7-Transdihydroxyligustilide is used for the research of hyperlipidemia.
    rel-(E)-6,7-Transdihydroxyligustilide
  • HY-N18145
    (3Z,5E,11E)-3,5,11-Tri-decatriene-7,9-diyne-1,2-diacetate 201012-53-5
    (3Z,5E,11E)-3,5,11-Tri-decatriene-7,9-diyne-1,2-diacetate is a human pancreatic lipase inhibitor, with an IC50 of 77.97 μM against human pancreatic lipase. (3Z,5E,11E)-3,5,11-Tri-decatriene-7,9-diyne-1,2-diacetate is applicable to the research of obesity.
    (3Z,5E,11E)-3,5,11-Tri-decatriene-7,9-diyne-1,2-diacetate
Cat. No. Product Name / Synonyms Application Reactivity